Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUK203-215 in Relapsed/Refractory Autoimmune Diseases
NCT07144462Phase 1Recruiting
- Sponsor
- Neukio Biotherapeutics
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEUK203-215 in systemic lupus erythematosus (SLE), diffuse cutaneous systemic sclerosis (dcSSc), inflammatory myopathy (IIM) and 1 more, sponsored by Neukio Biotherapeutics. Primary endpoints: Adverse Events at 12 months, Dose Limiting Toxicity at 12 months and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
NEUK203-215
03
Conditions
systemic lupus erythematosus (SLE)diffuse cutaneous systemic sclerosis (dcSSc)inflammatory myopathy (IIM)Autoimmune bullous dermatosis (AIBD)
Beyond the preview
Go deeper on NCT07144462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144462.